11:35 AM EDT, 10/31/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target to $77 from $89, about 32x our 2026 EPS, below DXCM's average forward P/E and slightly under MedTech peers. We lift our 2025 EPS by a penny to $2.03 but cut our 2026 EPS to $2.40 (from $2.55). Our revised estimates reflect slower-than-expected growth in 2026, as management noted on the call that the top end of its 2026 revenue forecast is below the Street's current expectation of roughly 15% growth. We now model about 13% revenue growth in 2026 (down from about 16%). Q3 results were solid, in our view, but likely fell short of high buy-side expectations, particularly given some margin softness. We maintain a Hold opinion, viewing shares as fairly valued following today's pullback. Downside risks include competition in glucose sensing, pricing pressure, and a potentially smaller type 2 diabetes population with greater GLP-1 drug adoption.